
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has dosed the first patient in the Phase 3 COMET-2 study to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease (DED).
This study is the first of three trials in the Phase 3 registrational program for AR-15512.